Workflow
HAOHAI BIOTEC(06826)
icon
Search documents
昊海生物科技(06826) - 2023 - 年度财报
2024-04-12 09:04
Financial Performance - Total revenue for 2023 reached RMB 2,634,910,000, an increase of 25.2% compared to RMB 2,103,438,000 in 2022[6] - Net profit attributable to shareholders was RMB 416,121,000, up 130.5% from RMB 180,470,000 in the previous year[6] - Earnings per share increased to RMB 2.44 in 2023, compared to RMB 1.04 in 2022[6] - The company achieved a total revenue of RMB 2,634.91 million in 2023, representing a year-on-year increase of 25.27%[7] - The company’s net profit attributable to ordinary shareholders was approximately RMB 416.12 million, an increase of about RMB 235.65 million or 130.58% from RMB 180.47 million in 2022[42] - The overall gross margin for the company was 70.34% in 2023, up from 68.79% in 2022, primarily due to strong sales performance of high-margin hyaluronic acid products[37] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 7,105,497,000, a rise from RMB 6,892,399,000 in 2022[6] - Total liabilities increased to RMB 1,088,204,000 from RMB 990,016,000 in 2022, resulting in a debt-to-asset ratio of 15.3%[6] - Total current liabilities of the group as of December 31, 2023, were approximately RMB 715.95 million, an increase of about RMB 204.67 million or 40.03% compared to December 31, 2022[43] - The total liabilities of the group as of December 31, 2023, were approximately RMB 1,088.20 million, with a debt-to-asset ratio of 15.31%, an increase of 0.95 percentage points from 14.36% as of December 31, 2022[48] Research and Development - Research and development efforts are focused on innovative technologies to enhance product offerings and competitiveness[6] - Research and development expenses amounted to RMB 220.10 million, an increase of 20.81% year-on-year, accounting for 8.35% of total revenue[11] - The company is actively developing innovative high-end artificial lens products, with several clinical trials underway for new technologies[18] - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with several innovative products entering the registration phase[11] Market Expansion and Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[6] - Management remains optimistic about future performance, expecting continued revenue growth and improved profitability[6] - The company is exploring potential mergers and acquisitions to accelerate growth and market expansion[6] - The company aims to expand its market share in the medical aesthetics sector by promoting its differentiated hyaluronic acid products through a broad sales network in 2024[36] Product Performance - The ophthalmic product line generated revenue of RMB 924.65 million, accounting for 35.10% of total revenue, with a growth rate of 20.72%[10] - The medical beauty and wound care product line saw revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a year-on-year growth of 41.44%[10] - The company's hyaluronic acid product line includes three generations, with the first generation achieving sales of RMB 599.41 million, accounting for 56.94% of total revenue in 2023, reflecting a growth of 95.78% year-on-year[23] - The company's ophthalmic products achieved revenue of RMB 924.65 million, an increase of approximately RMB 158.68 million, representing a growth rate of 20.72% compared to the previous year[14] Shareholder Returns - The board proposed a final dividend of RMB 1.00 per share for the year 2023, reflecting a 150% increase compared to the previous year[7] - The company plans to distribute a final dividend of RMB 1.00 per share for the year ending December 31, 2023, totaling RMB 167,360,375.00[58] - The company’s profit distribution policy emphasizes a stable and sustainable return to investors, with cash dividends prioritized when conditions allow[64] Corporate Governance - The company has established a corporate governance structure to protect shareholder rights and enhance accountability[123] - The company has adhered to all applicable provisions of the corporate governance code during the reporting period[117] - The board consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors[123] - The company has established internal policies to ensure the board receives independent views and opinions, with independent non-executive directors entitled to seek independent professional advice at the company's expense[127] Risk Management - The company has established a stable and effective risk management mechanism, including an internal audit system and risk assessment management system[183] - The company faces potential risks from intensified market competition, which could impact its market share and profitability[157] - Regulatory changes in China's healthcare system may increase compliance costs and reduce product demand if the company fails to adapt[158] Employee and Management - The total employee compensation for the group during the reporting period was approximately RMB 630.08 million, with a total workforce of 2,158 employees[44] - The company has implemented a restricted stock incentive plan approved on March 7, 2022, to attract and retain core management and technical personnel, with a total of 1,800,000 shares granted under this plan[91] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[84] Community and Social Responsibility - The company made donations amounting to RMB 100,000 during the reporting period[119] - Community engagement includes donations, public welfare activities, and industry meetings[200] Compliance and Legal Matters - The company has not encountered any corruption or bribery lawsuits during the reporting period, reflecting its commitment to integrity and compliance[186] - The company has complied with all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules regarding related party transactions[116]
昊海生物科技(06826) - 2023 - 年度业绩
2024-03-08 13:05
Financial Performance - The company recorded a total revenue of RMB 2,634.91 million for the year ended December 31, 2023, representing an increase of RMB 531.47 million or 25.27% compared to the previous year[2]. - Net profit attributable to shareholders was approximately RMB 416.12 million, reflecting a growth of 130.58% compared to the previous year, while the net profit excluding non-recurring items was RMB 383.41 million, up 141.52%[2]. - The gross profit for the year was RMB 1,853.51 million, compared to RMB 1,446.92 million in 2022, indicating a significant increase in profitability[3]. - The company reported a total comprehensive income of RMB 404.44 million for the year, significantly higher than RMB 100.70 million in 2022[4]. - The basic and diluted earnings per share for the year were RMB 2.44, compared to RMB 1.04 in the previous year, showcasing strong earnings growth[4]. - The total tax expense for the year 2023 amounted to RMB 95,991,000, an increase of 111.1% compared to RMB 45,395,000 in 2022[30]. Research and Development - Research and development expenses amounted to approximately RMB 220.10 million, an increase of RMB 37.91 million or 20.81% year-over-year, accounting for 8.35% of total revenue[2]. - The company is focusing on expanding its ophthalmic and aesthetic innovation product lines, with several key R&D projects progressing smoothly[48]. - The hydrophobic injection aspheric intraocular lens product has been approved for registration and market launch in June 2023, while other products are in various stages of clinical trials and registration[48]. - The company has initiated clinical trials for the innovative hydrophobic molded aspheric trifocal artificial lens in July 2023[56]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 1.00 per share for the year ended December 31, 2023, compared to RMB 0.40 per share in 2022, and recommended a bonus issue of 4 new shares for every 10 existing shares[2]. - The total number of H-shares repurchased in 2023 was 3,872,400, with a total expenditure of HKD 166,589,234.00[89]. - The total number of A-shares repurchased in 2023 was 1,089,486, with a total expenditure of RMB 117,145,262.95[90]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 6,389.55 million, slightly up from RMB 6,381.12 million in the previous year[5]. - Current assets increased to RMB 3,750.14 million from RMB 3,532.12 million, indicating improved liquidity[5]. - The company’s total liabilities amounted to RMB 407.95 million as of December 31, 2023, compared to RMB 118.26 million in 2022[40]. - The current portion of total liabilities was RMB 216.63 million, while the non-current portion was RMB 191.32 million[40]. Revenue Breakdown - Revenue from mainland China was RMB 2,181,814 thousand, up 28.5% from RMB 1,699,078 thousand in 2022[22]. - The ophthalmology product line generated RMB 924.65 million in revenue, accounting for 35.10% of total revenue, with a year-on-year growth of 20.72%[47]. - The medical beauty and wound care product line reported revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a significant year-on-year growth of 41.44%[47]. - The orthopedic product line's revenue reached RMB 474.26 million, making up 18.00% of total revenue, with a year-on-year increase of 22.71%[47]. Market Position and Strategy - The company has been recognized as a high-tech enterprise, allowing a preferential tax rate of 15% for certain subsidiaries in 2023[6]. - The company aims to accelerate the localization of the ophthalmic industry in China and become a globally recognized comprehensive ophthalmic product manufacturer[50]. - The company has established exclusive distribution rights for high-end corneal reshaping lenses in mainland China, enhancing its market share and influence[56]. - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, while enhancing research and development capabilities[69]. Compliance and Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[93]. - The audit committee reviewed the audited consolidated financial statements and annual results for the year ending December 31, 2023[94]. - The annual report containing all data required by the Hong Kong Listing Rules will be sent to shareholders and published on the relevant websites in due course[95].
昊海生科:H股公告:翌日披露报表
2023-12-07 09:12
FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2023年12月6日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年12月5日 | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | 30,000 | 0.0175 % | | | ...
昊海生科:上海昊海生物科技股份有限公司2023年第二次临时股东大会会议资料
2023-12-07 09:10
证券代码:688366 证券简称:昊海生科 上海昊海生物科技股份有限公司 2023 年第二次临时股东大会 会议资料 二〇二三年十二月二十九日·上海 1 | 会议须知 1 | | --- | | 会议议程 3 | | 关于选举独立非执行董事的议案 4 | | 关于修订《上海昊海生物科技股份有限公司独立董事工作细则》的议案 5 | 上海昊海生物科技股份有限公司 2023 年第二次临时股东大会 会议须知 为了维护全体股东的合法权益、确保股东大会的正常秩序和议事效率,保证 股东大会的顺利进行,上海昊海生物科技股份有限公司(以下简称"公司")根 据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》、 中国证券监督管理委员会《上市公司股东大会规则》以及《上海昊海生物科技股 份有限公司章程》、《上海昊海生物科技股份有限公司股东大会议事规则》等相关 规定,特制定本须知,请全体出席股东大会的人员自觉遵守。 一、为确认出席大会的股东或其代理人或其他出席者的出席资格,会议工作 人员将对出席会议者的身份进行必要的核对工作,请被核对者给予配合。 二、经公司审核后符合参加本次股东大会条件的股东(含股东代理人)、 ...
昊海生科:上海昊海生物科技股份有限公司关于召开2023年第二次临时股东大会的通知
2023-12-07 09:08
重要内容提示: 一、 召开会议的基本情况 证券代码:688366 证券简称:昊海生科 公告编号:2023-063 上海昊海生物科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 (一) 股东大会类型和届次 2023 年第二次临时股东大会 召开日期时间:2023 年 12 月 29 日 13 点 00 分 召开地点:上海市长宁区虹桥路 1386 号文广大厦 24 楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自 2023 年 12 月 29 日 至 2023 年 12 月 29 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段,即 9:15-9:25,9:30-11:30,13:00-15:00;通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期:2023年12月29日 本次股东大会采用的网络投票系统:上 ...
昊海生科:H股公告:翌日披露报表
2023-12-05 09:46
FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2023年12月5日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年12月4日 | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | 65,700 | 0.0383 % | | | ...
昊海生科:H股公告:截至二零二三年十一月三十日止月份股份发行人的证券变动月报表
2023-12-05 09:44
FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2023年12月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 06826 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 32,895,100 | RMB | | 1 RMB | | | 32,895,100 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | 0 | | 本月底結存 | | | 32,895,100 | RMB | | 1 RMB | ...
昊海生科:H股公告:翌日披露报表
2023-12-04 09:36
FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2023年12月4日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 | H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月24日 | | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 37,00 ...
昊海生科:上海昊海生物科技股份有限公司关于使用暂时闲置募集资金进行现金管理的公告
2023-12-01 11:50
证券代码:688366 证券简称:昊海生科 公告编号:2023-059 为规范公司募集资金管理和使用,保护投资者权益,公司设立了相关募集资 金专项账户。募集资金到账后,已全部存放于经公司董事会批准开设的募集资金 专项账户内,公司已与保荐机构、存放募集资金的商业银行签署了募集资金三方 监管协议。详细情况请参见公司已于2019年10月29日披露于上海证券交易所网站 (www.sse.com.cn)的《昊海生科首次公开发行股票科创板上市公告书》。 上海昊海生物科技股份有限公司 由于募集资金投资项目建设需要一定周期且根据公司募集资金的使用计划, 公司的部分募集资金存在暂时闲置的情形。 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ●上海昊海生物科技股份有限公司(以下简称"公司"或"昊海生科")拟在保 证不影响公司募集资金投资计划正常进行的前提下,使用最高不超过人民币 61,000万元的暂时闲置募集资金进行现金管理,用于购买安全性高、流动性好、 有保本约定的投资产品(包括 ...
昊海生科:上海昊海生物科技股份有限公司关于以集中竞价交易方式回购公司A股股份的进展公告
2023-12-01 11:50
重要内容提示: 证券代码:688366 证券简称:昊海生科 公告编号:2023-062 上海昊海生物科技股份有限公司 关于以集中竞价交易方式回购公司A股股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 ● 截至 2023 年 11 月 30 日,上海昊海生物科技股份有限公司(以下简称 "公司")已累计回购公司 A 股股份 1,079,084 股,占公司总股本 171,331,156 股 的比例为 0.63%,最高成交价为 113.50 元/股,最低成交价为 96.19 元/股,成交 总金额为人民币 116,116,001.73 元(不含印花税、交易佣金等交易费用)。 一、回购股份基本情况 公司分别于2023年8月24日、2023年9月15日召开第五届董事会第十四次会议, 2023年第一次临时股东大会、2023年第二次A股类别股东大会及2023年第二次H 股类别股东大会(以下合称"股东大会")审议通过了《关于以集中竞价交易方 式回购公司A股股份方案的议案》,同意公司以集中竞价交易方式回购公司A股 股份,回购资金 ...